Saturday, May 31, 2025

Latest

PharmaTher Files Patent For Use Of Ketamine In Type 2 Diabetes, Obesity

PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the filing of a provisional patent application in the US for the novel use of ketamine as a potential treatment for Type 2 diabetes and obesity.

The filing of the patent for the indication follows the company evaluating various indications with panaceAI, which is the firms artificial intelligence platform. The platform has reportedly discovered protein bindings and interactions with ketamine that have lead to the compound being a potential treatment for diabetes and obesity. The tech is also reportedly currently evaluating DMT, MDMA, and LSD for future partnering opportunities and clinical development.

An application with the FDA has also been submitted for the use of ketamine as a potential treatment for parkinsons disease under an investigation new drug designation. If accepted, the company intends to expand the phase 2 clinical trial to include these new indications.

“We continue to focus on building our patent and product portfolio of prescription-based psychedelics through our drug repurposing and delivery methods for unmet medical needs. Our strategy is to investigate ketamine in FDA Phase 2 clinical trials for Parkinson’s disease and depression and with panaceAI™, we aim to find new uses of psychedelics, such as ketamine, psilocybin, DMT, MDMA and LSD, and incorporate them into our proprietary microneedle patch delivery system.”

Fabio Chianelli, CEO of PharmaTher

PharmaTher last traded at $0.24 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Alamos Gold Q1 Earnings: The Inside Scoop

Cerrado Gold Q4 Earnings: The Turnaround is Working

B2GOLD Q1 Earnings: Revenue Up, Production & Cash Flow Decline

Recommended

Canadian Copper: The $172M Combined Strategy PEA

ESGold Begins Concentration Tests Ahead Of First Production

Related News

Pharmather Acquires Exclusive License For Ketamine Treatment Against Parkinson’s Disease

Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive licensing...

Thursday, October 15, 2020, 09:02:27 AM

PharmaTher Files Patent Application In US For Psilocybin Drug Combination To Treat Neurological Disorders

PharmaTher Inc (CSE: PHRM) this morning announced that it has filed a provisional patent application...

Tuesday, December 15, 2020, 09:00:13 AM

Pharmather Appoints Dr Alberto J Espay As Scientific Advisor

Pharmather Inc (CSE: PHRM) has appointed a prolific Parkinson’s researcher to its team of scientific...

Wednesday, November 11, 2020, 08:29:13 AM

Pharmather Enters Exclusive Arrangement For Psychedelic Delivery Tech

Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive license...

Thursday, October 22, 2020, 08:13:19 AM

PharmaTher Acquires Exclusive Rights To Patented Ketamine Formulation

PharmaTher Inc (CSE: PHRM) has entered into an exclusive worldwide license agreement for the development...

Tuesday, January 19, 2021, 09:24:20 AM